Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Closing The Books On GDUFA II
How Generics Fared At US FDA Over The Last Five Years
18 Oct 2022
•
By
Derrick Gingery
Approval and submission data indicate steady trends aside from one outlier year.
About 16% of ANDA approvals in FY 2022 were first-time generic drugs • Source: Shutterstock
More from Generics
More from Products